ARHGAP35 and endometrial cancer: It should be noted that inactivation of ARHGAP35 leads to abnormal activation of RhoA in endometrial cancer and promotes the malignant transformation of tumor cells through the Hippo-Yap pathway [51], consistent with the conclusions reported in this study.